{"id":1856,"date":"2026-09-07T06:00:00","date_gmt":"2026-09-06T21:00:00","guid":{"rendered":"https:\/\/onepress.co.kr\/index.php\/briefing\/2026-09-07-h3n2-subclade-k-neutralisation-en\/"},"modified":"2026-09-07T06:00:00","modified_gmt":"2026-09-06T21:00:00","slug":"2026-09-07-h3n2-subclade-k-neutralisation-en","status":"publish","type":"briefing","link":"https:\/\/onepress.co.kr\/index.php\/briefing\/2026-09-07-h3n2-subclade-k-neutralisation-en\/","title":{"rendered":"H3N2 subclade K evaded antibodies, but neutralisation rose after vaccination"},"content":{"rendered":"

2026-09-07 06:00 KST<\/strong><\/p>\n

The H3N2 subclade K that spread in 2025 entered some cell lines more efficiently and escaped existing antibodies, yet neutralising activity in human serum rose significantly after vaccination. The September 4 study linked much of both behaviour to the A186D change in haemagglutinin.<\/p>\n

This is not proof that vaccination prevents every infection. Researchers used particles bearing influenza surface proteins to measure cell entry and antibody neutralisation in the laboratory; they did not follow people for infection, hospitalisation or death.<\/p>\n

What was compared?<\/h2>\n

The team compared vaccine-matched H3N2 proteins with late-2025 subclade K proteins across cell lines and paired serum collected before and after vaccination.<\/p>\n

What did it find?<\/h2>\n

K entered selected cells more efficiently and resisted pre-vaccination antibodies, while vaccination markedly raised neutralising titres. The paper does not convert that rise into a clinical protection percentage.<\/p>\n

\"H3N2
This AI-generated image explains the topic; it is not a photograph of the actual event, observation, or experiment.<\/figcaption><\/figure>\n

Why does A186D matter?<\/h2>\n

Reversing A186D reduced both enhanced entry and antibody escape, suggesting one haemagglutinin change affects receptor use and antigenic shape. It is not the sole determinant of disease.<\/p>\n

What should people do?<\/h2>\n

The result does not justify choosing a product independently or dropping other precautions. Real effectiveness varies by age, health, timing and circulating viruses; follow current national guidance.<\/p>\n

What comes next?<\/h2>\n

Surveillance and real-world effectiveness studies must test whether laboratory neutralisation translates into fewer infections and severe outcomes. WHO composition updates remain the official reference.<\/p>\n

Primary sources and independent checks<\/h2>\n

npj Vaccines \uc6d0 \ub17c\ubb38<\/a><\/p>\n

\uc601\uad6d \ubcf4\uac74\uc548\ubcf4\uccad 2025~2026 \uacc4\uc808 \ud3c9\uac00<\/a><\/p>\n

WHO 2026~2027 \ubd81\ubc18\uad6c \ubc31\uc2e0 \uc870\uc131 \uad8c\uace0<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

A laboratory study found increased antibody escape and cell entry for subclade K, while post-vaccination sera neutralised it substantially better. It did not directly measure clinical effectiveness.<\/p>\n","protected":false},"featured_media":0,"template":"","meta":[],"class_list":["post-1856","briefing","type-briefing","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/onepress.co.kr\/index.php\/wp-json\/wp\/v2\/briefing\/1856","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/onepress.co.kr\/index.php\/wp-json\/wp\/v2\/briefing"}],"about":[{"href":"https:\/\/onepress.co.kr\/index.php\/wp-json\/wp\/v2\/types\/briefing"}],"wp:attachment":[{"href":"https:\/\/onepress.co.kr\/index.php\/wp-json\/wp\/v2\/media?parent=1856"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}